Literature DB >> 11448281

Validation of the Framingham coronary heart disease prediction scores: results of a multiple ethnic groups investigation.

R B D'Agostino1, S Grundy, L M Sullivan, P Wilson.   

Abstract

CONTEXT: The Framingham Heart Study produced sex-specific coronary heart disease (CHD) prediction functions for assessing risk of developing incident CHD in a white middle-class population. Concern exists regarding whether these functions can be generalized to other populations.
OBJECTIVE: To test the validity and transportability of the Framingham CHD prediction functions per a National Heart, Lung, and Blood Institute workshop organized for this purpose. DESIGN, SETTING, AND
SUBJECTS: Sex-specific CHD functions were derived from Framingham data for prediction of coronary death and myocardial infarction. These functions were applied to 6 prospectively studied, ethnically diverse cohorts (n = 23 424), including whites, blacks, Native Americans, Japanese American men, and Hispanic men: the Atherosclerosis Risk in Communities Study (1987-1988), Physicians' Health Study (1982), Honolulu Heart Program (1980-1982), Puerto Rico Heart Health Program (1965-1968), Strong Heart Study (1989-1991), and Cardiovascular Health Study (1989-1990). MAIN OUTCOME MEASURES: The performance, or ability to accurately predict CHD risk, of the Framingham functions compared with the performance of risk functions developed specifically from the individual cohorts' data. Comparisons included evaluation of the equality of relative risks for standard CHD risk factors, discrimination, and calibration.
RESULTS: For white men and women and for black men and women the Framingham functions performed reasonably well for prediction of CHD events within 5 years of follow-up. Among Japanese American and Hispanic men and Native American women, the Framingham functions systematically overestimated the risk of 5-year CHD events. After recalibration, taking into account different prevalences of risk factors and underlying rates of developing CHD, the Framingham functions worked well in these populations.
CONCLUSIONS: The sex-specific Framingham CHD prediction functions perform well among whites and blacks in different settings and can be applied to other ethnic groups after recalibration for differing prevalences of risk factors and underlying rates of CHD events.

Entities:  

Mesh:

Year:  2001        PMID: 11448281     DOI: 10.1001/jama.286.2.180

Source DB:  PubMed          Journal:  JAMA        ISSN: 0098-7484            Impact factor:   56.272


  654 in total

1.  Validation of an atrial fibrillation risk algorithm in whites and African Americans.

Authors:  Renate B Schnabel; Thor Aspelund; Guo Li; Lisa M Sullivan; Astrid Suchy-Dicey; Tamara B Harris; Michael J Pencina; Ralph B D'Agostino; Daniel Levy; William B Kannel; Thomas J Wang; Richard A Kronmal; Philip A Wolf; Gregory L Burke; Lenore J Launer; Ramachandran S Vasan; Bruce M Psaty; Emelia J Benjamin; Vilmundur Gudnason; Susan R Heckbert
Journal:  Arch Intern Med       Date:  2010-11-22

2.  Adherence index based on the AHA 2006 diet and lifestyle recommendations is associated with select cardiovascular disease risk factors in older Puerto Ricans.

Authors:  Shilpa N Bhupathiraju; Alice H Lichtenstein; Bess Dawson-Hughes; Katherine L Tucker
Journal:  J Nutr       Date:  2011-01-26       Impact factor: 4.798

3.  Evaluation of the Pooled Cohort Risk Equations for Cardiovascular Risk Prediction in a Multiethnic Cohort From the Women's Health Initiative.

Authors:  Samia Mora; Nanette K Wenger; Nancy R Cook; Jingmin Liu; Barbara V Howard; Marian C Limacher; Simin Liu; Karen L Margolis; Lisa W Martin; Nina P Paynter; Paul M Ridker; Jennifer G Robinson; Jacques E Rossouw; Monika M Safford; JoAnn E Manson
Journal:  JAMA Intern Med       Date:  2018-09-01       Impact factor: 21.873

4.  Refractory hypertension: determination of prevalence, risk factors, and comorbidities in a large, population-based cohort.

Authors:  David A Calhoun; John N Booth; Suzanne Oparil; Marguerite R Irvin; Daichi Shimbo; Daniel T Lackland; George Howard; Monika M Safford; Paul Muntner
Journal:  Hypertension       Date:  2013-12-09       Impact factor: 10.190

5.  Interethnic differences in the accuracy of anthropometric indicators of obesity in screening for high risk of coronary heart disease.

Authors:  V M Herrera; J P Casas; J J Miranda; P Perel; R Pichardo; A González; J R Sanchez; C Ferreccio; X Aguilera; E Silva; M Oróstegui; L F Gómez; J A Chirinos; J Medina-Lezama; C M Pérez; E Suárez; A P Ortiz; L Rosero; N Schapochnik; Z Ortiz; D Ferrante; M Diaz; L E Bautista
Journal:  Int J Obes (Lond)       Date:  2009-02-24       Impact factor: 5.095

Review 6.  Insulin Resistance and Atherosclerosis: Implications for Insulin-Sensitizing Agents.

Authors:  Antonino Di Pino; Ralph A DeFronzo
Journal:  Endocr Rev       Date:  2019-12-01       Impact factor: 19.871

7.  Comparison of coronary heart disease risk among four diagnostic definitions of metabolic syndrome.

Authors:  T Suzuki; Z Zeng; B Zhao; Z Wei; M Tanabe; T Shimbo; H Kajio; N Kato; M Naruse
Journal:  J Endocrinol Invest       Date:  2016-08-29       Impact factor: 4.256

Review 8.  Framingham-based tools to calculate the global risk of coronary heart disease: a systematic review of tools for clinicians.

Authors:  Stacey Sheridan; Michael Pignone; Cynthia Mulrow
Journal:  J Gen Intern Med       Date:  2003-12       Impact factor: 5.128

9.  Impact on cardiovascular disease events of the implementation of Argentina's national tobacco control law.

Authors:  Jonatan Konfino; Daniel Ferrante; Raul Mejia; Pamela Coxson; Andrew Moran; Lee Goldman; Eliseo J Pérez-Stable
Journal:  Tob Control       Date:  2012-10-23       Impact factor: 7.552

10.  Basic vs More Complex Definitions of Family History in the Prediction of Coronary Heart Disease: The Multi-Ethnic Study of Atherosclerosis.

Authors:  Jaideep Patel; Mahmoud Al Rifai; Maren T Scheuner; Steven Shea; Roger S Blumenthal; Khurram Nasir; Michael J Blaha; John W McEvoy
Journal:  Mayo Clin Proc       Date:  2018-03-16       Impact factor: 7.616

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.